Naphthalene Sulfonic Acids and Salts (NSAs) Group

These substances were identified for action under the Chemicals Management Plan (CMP). This screening assessment focuses on 6 of 7 substances referred to collectively as the Naphthalene Sulfonic Acids and Salts (NSAs) Group.

Summary of publications
Substance group CAS RN Acronym DSL name Draft screening assessment Proposed conclusion on section 64 criteria Follow-up activities
NSAs Group 1321-69-3Footnote a NaNSA Naphthalenesulfonic acid, sodium salt HTML Does not meet None planned at this time
25322-17-2Footnote a, Footnote c DNNSA Naphthalenesulfonic acid, dinonyl-
25619-56-1Footnote a, Footnote c BaDNNSA Naphthalenesulfonic acid, dinonyl-, barium salt
57855-77-3Footnote a, Footnote b CaDNNSA Naphthalenesulfonic acid, dinonyl-, calcium salt
60223-95-2Footnote a, Footnote c DNNDSA Naphthalenedisulfonic acid, dinonyl-
68425-61-6Footnote a CDINSA Naphthalenesulfonic acid, bis(1-methylethyl)-, compd. with cyclohexanamine (1:1)
Footnote a

Substance is a UVCB (unknown or variable composition, complex reaction products, or biological materials).

Return to footnote a referrer

Footnote b

This substance was not identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999 but was included in this assessment as it was considered a priority on the basis of other human health concerns.

Return to footnote b referrer

Footnote c

This substance was determined to be a priority as a result of the approach described for the Identification of Risk Assessment Priorities.

Return to footnote c referrer

Timelines
Date Activity
July 2021 Anticipated publication of the final screening assessment.
July 4, 2020 Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 154, No. 27.

Background

One other substance was identified as being a part of the NSAs Group at the outset of the third phase of the CMP. This substance was subsequently determined to be of low concern to both human health and the environment, through other approaches. Conclusions for the substance with CAS RN 25638-17-9 are provided in the Final Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: